Italian region weighs up thalassaemia R&D (research and development) options:
This article was originally published in Clinica
Italy's Marche region has declined an offer by the central government to transform the San Salvatore hospital, Pesaro, into a national centre for research into thalassaemia. During a meeting last week with the ministers of health and of the economy, the regional authorities said they were considering giving foundation status to only part of the hospital, namely the haematology department. The health ministry has expressed regret at the decision, since the centre will miss the opportunity of becoming part of the national and European networks of centres of research excellence. Neither will the centre be entitled to the substantial funding the government has set aside in 2002 for this programme. The Marche region has yet to formally announce its decision to the central government.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.